GlassScriptPhysician profile
Salman Waheeduddin
NPI 1598700387
$4,844.36
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $3,298 · 2021: $225 · 2022: $401 · 2023: $634 · 2024: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.56 |
| Education | $125.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,735.47 | 2020-2024 | Skyrizi, Rinvoq, Humira |
| Genzyme Corporation | $286.74 | 2023-2024 | |
| Amgen INC. | $204.20 | 2022-2024 | Enbrel, Otezla, Tavneos |
| Glaxosmithkline, LLC. | $197.91 | 2022 | |
| Aurinia Pharma U.S., INC. | $144.28 | 2023 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $124.88 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $99.99 | 2023 | Opsumit, Uptravi |
| Celltrion USA INC. | $25.49 | 2024 | Yuflyma |
| Lilly USA, LLC | $25.40 | 2023 | Taltz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salman Waheeduddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.